文献速递免疫规划妇幼与学校卫生

南非HIV暴露未感染与未暴露儿童甲肝和水痘疫苗短期免疫原性与安全性

Short-term immunogenicity and safety of hepatitis-A and varicella vaccines in HIV-exposed uninfected and HIV-unexposed South African children.
PubMed 文献 · Vaccine · 2020-04-16

195名HIV未暴露和64名HIV暴露未感染儿童在18月龄接种单剂甲肝灭活疫苗或水痘减毒活疫苗,接种后1个月甲肝血清阳性率两组相似(91.8% vs 82.9%,p=0.144),水痘抗体几何平均倍数上升两组相似,但仅44%的HIV未暴露和HIV暴露未感染儿童血清转化,不良事件频率和严重程度两组相似,但HIV暴露未感染儿童水痘接种后全身不良事件更多。

要点

  • 单剂甲肝和水痘疫苗在HIV暴露未感染与未暴露儿童中免疫原性相似。
  • 接种后1个月甲肝血清阳性率HIV未暴露91.8% vs HIV暴露未感染82.9%(p=0.144)。
  • 仅44%的HIV未暴露和HIV暴露未感染儿童水痘血清转化(滴度>50 mIU/ml)。

核心结论

  • 单剂甲肝和水痘疫苗在HIV未暴露与HIV暴露未感染儿童中免疫原性相似,接种活减毒或灭活疫苗后短期体液免疫未见差异。
  • 单剂水痘疫苗血清转化率低于既往研究报告的85-89%。

研究设计与样本

  • 195名HIV未暴露和64名HIV暴露未感染南非儿童在18月龄接种单剂甲肝灭活疫苗或水痘减毒活疫苗。
  • 接种前和接种后1个月分别用化学发光微粒子免疫分析法和酶联免疫吸附试验检测甲肝或水痘抗体。
  • 所有儿童评估征集性不良事件。

主要发现

  • 接种后1个月,HIV未暴露儿童甲肝血清阳性率为91.8%,HIV暴露未感染儿童为82.9%(p=0.144)。
  • 水痘抗体几何平均倍数上升在HIV未暴露儿童为5.6(95%CI:4.6-6.7),在HIV暴露未感染儿童为5.1(95%CI:3.7-7.2)。
  • 仅44%的HIV未暴露和HIV暴露未感染儿童水痘血清转化(滴度>50 mIU/ml)。
  • 不良事件频率和严重程度两组相似,但HIV暴露未感染儿童水痘接种后全身不良事件多于HIV未暴露儿童。

局限性

  • 单剂水痘疫苗血清转化率低于既往研究报告的85-89%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: HIV-exposed uninfected (HEU) children have increased risk of infectious morbidity during early childhood. We evaluated the short-term immunogenicity and safety of single dose inactivated hepatitis-A virus (HAV) vaccine and live attenuated varicella zoster virus (VZV) vaccine in South African children. METHODS: 195 HIV-unexposed and 64 HEU children received either one dose of HAV or VZV vaccine at 18 months of age. Blood samples were tested for hepatitis-A or VZV antibodies before and one month after vaccination by chemiluminescent microparticle immunoassay and enzyme-linked immunosorbent assay, respectively. All children were evaluated for solicited adverse events (AEs). RESULTS: One-month post-vaccination, a similar percentage of HIV-unexposed (91.8%) and HEU (82.9%) children were seropositive for hepatitis-A (p = 0.144). VZV antibody geometric mean fold-rise was also similar in HIV-unexposed (5.6; 95%CI: 4.6-6.7) and HEU children (5.1; 95%CI: 3.7-7.2); however, only 44% HIV-unexposed and HEU seroconverted (titers > 50 mIU/ml). AEs occurred with similar frequency and severity between groups, except for more systemic AEs after VZV vaccination in HEU than HIV-unexposed children. CONCLUSIONS: Single dose HAV and VZV vaccine was similarly immunogenic in HIV-unexposed and HEU children. We did not identify differences in short-term humoral immunity after administration of either a live attenuated or inactivated vaccine. Seroconversion rates after a single dose of VZV vaccine were, however, lower compared to reports from previous studies (85-89%). CLINICAL TRIALS REGISTRATION: NCT03330171.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Mutsaerts EAML, Nunes MC, Bhikha S, et al. Short-term immunogenicity and safety of hepatitis-A and varicella vaccines in HIV-exposed uninfected and HIV-unexposed South African children. Vaccine. 2020. PMID: 32307279. doi:10.1016/j.vaccine.2020.03.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。